Immune cell army targets childhood cancers that Won't quit
NCT ID NCT05400603
First seen Nov 01, 2025 · Last updated Jun 11, 2026 · Updated 26 times
Summary
This early-phase study tests a new treatment for children whose neuroblastoma or osteosarcoma has returned or not responded to standard therapy. The approach combines a special type of immune cell (gamma delta T cells) from a healthy donor with chemotherapy and other drugs to help the body fight the cancer. The main goals are to find the safest dose and understand side effects. Up to 24 children aged 1 and older will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Healthcare of Atlanta
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.